Iloperidone, asenapine and lurasidone: a primer on their current status
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Three newer atypical antipsychotic drugs were FDA-approved in 2009 and 2010 in the following order: iloperidone, asenapine and lurasidone. The three drugs are indicated for the treatment of acute schizophrenia. Asenapine is also approved for treatment of manic or mixed episodes associated with bipolar I disorder, for the maintenance treatment of schizophrenia and as an adjunctive therapy with lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. AREAS COVERED: This review compares and contrasts the current preclinical, clinical, safety and tolerability profiles of the three newer drugs, as reported in published preclinical and clinical studies, product labels, poster presentations and press releases. EXPERT OPINION: Preclinical studies have reported that the three drugs have variable affinities for a wide range of neurotransmitter receptors, and are active in animal models predictive of antipsychotic activity. Asenapine is the first antipsychotic to be administered sublingually, whereas iloperidone requires titration to minimize orthostatic hypotension. Asenapine and lurasidone are associated with dose-related akathisia, whereas iloperidone is not. The three drugs appear to have relatively benign metabolic profiles. The availability of the three novel antipsychotics should provide additional options for improved treatment of schizophrenia and other psychotic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Moreover, large-scale clinical trials (CATIE and CUtLASS) suggested that the efficacies of atypical antipsychotics are not superior to older typical agents in chronic schizophrenia patients [19,20].”
BackgroundClozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · cited 1×
“Clozapine, the prototype of atypical antipsychotics was another breakthrough in the treatment of schizophrenia [7-9].”
BackgroundJones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Goodman and Gilman's The Pharmacological Basis of Therapeutics.
(1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-3-453_1 · Cited by 1,011
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 1×
“However, these agents exhibit differences in terms of their efficacies, safety and adherence [14], and are also associated with undesirable side effects such as weight gain and metabolic deficits [15-18].”
BackgroundThe Burden of Schizophrenia on Caregivers: A Review
Awad, A. G., & Voruganti, L. N. P. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826020-00005 · Cited by 809
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714 · cited 1×
“However, these agents exhibit differences in terms of their efficacies, safety and adherence [14], and are also associated with undesirable side effects such as weight gain and metabolic deficits [15-18].”
BackgroundClozapine: A Novel Antipsychotic Agent
Oates, J. A., Wood, A. J. J., Baldessarini, R. J., & Frankenburg, F. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241107 · Cited by 687
Binding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607 · cited 1×
“Iloperidone has high affinity for adrenergic a1 (Ki < 5 nM) and a2C (Ki = 16 nM) receptors, which suggests a higher risk of dizziness, syncope and orthostatic hypotension [22].”
BackgroundMeltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602 · cited 1×
“Clozapine, the prototype of atypical antipsychotics was another breakthrough in the treatment of schizophrenia [7-9].”
Background5-HT1A receptor function in major depressive disorder
Savitz, J., Lucki, I., & Drevets, W. C. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.009 · Cited by 574 · cited 1×
“The partial agonist activity of asenapine and lurasidone at 5-HT1A receptors further support their potential utility in the treatment of anxiety and depressive disorders, as dysregulation of 5-HT1A receptors has been proposed to play a key role in the pathophysiology and treatment of these disorders [82,83].”
BackgroundA Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504
Self-citationAsenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid, M., Walker, G., Zorn, S., & Wong, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881107082944 · Cited by 493 · cited 1×
“2 nM), but much lower affinity for cholinergic receptors [26].”
BackgroundIshibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167346 · Cited by 438 · cited 4×
“In animal models predictive of EPS, higher doses of lurasidone (up to 1000 mg/kg) did not induce catalepsy in rats and had no effect on forepaw retractive time and poledescending time [38].”
BackgroundInfluentialThe Serotonin-1A Receptor in Anxiety Disorders
Akimova, E., Lanzenberger, R., & Kasper, S. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.012 · Cited by 360 · cited 1×
“The partial agonist activity of asenapine and lurasidone at 5-HT1A receptors further support their potential utility in the treatment of anxiety and depressive disorders, as dysregulation of 5-HT1A receptors has been proposed to play a key role in the pathophysiology and treatment of these disorders [82,83].”
BackgroundEffects of Newer Antipsychotics on Extrapyramidal Function
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002) · CNS Drugs · doi:10.2165/00023210-200216010-00003 · Cited by 313
Self-citationMillan, M. J. (2005) · Therapies · doi:10.2515/therapie:2005065 · Cited by 283 · cited 1×
“Asenapine’s and iloperidone’s high affinity and antagonistic activity at 5-HT7 receptors may support their potential efficacy in the treatment of uni-polar and bi-polar depression as blocking these receptors have been implicated in the pharmacotherapy of depression [78,79].”
BackgroundMantovani, A., Simpson, H. B., Fallon, B. A., Rossi, S., & Lisanby, S. H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990435 · Cited by 281
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl, S. M., Mignon, L., & Meyer, J. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01334.x · Cited by 259 · cited 1×
“However, these agents exhibit differences in terms of their efficacies, safety and adherence [14], and are also associated with undesirable side effects such as weight gain and metabolic deficits [15-18].”
BackgroundSelf-citationKane, J. M., Lauriello, J., Laska, E., Di Marino, M., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169cca7 · Cited by 250 · cited 4×
“In a long-term trial of iloperidone versus haloperidol, BAS scores worsened in 9% of iloperidone-treated patients versus 24% of haloperidol-treated patients [59].”
BackgroundInfluentialMeltzer, H. Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu, J., Kalali, A. H., Schweizer, E., Pikalov, A., & Loebel, A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10060907 · Cited by 250 · cited 1×
“Lurasidone (40 and 120 mg/day) and olanzapine (15 mg/kg) were statistically superior to placebo on CGI-S, PANSS-total, PANSSpositive, PANSS-negative scales [71].”
BackgroundThe metabolic syndrome and schizophrenia
Meyer, J. M., & Stahl, S. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01317.x · Cited by 245
Self-citationStahl, S. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017089 · Cited by 241 · cited 1×
“The high affinity and antagonistic activity of asenapine at histamine H1 receptors suggest that this drug might be effective in management of insomnia, which concur with many psychiatric disorders, without being a scheduled medication, which is typical of most hypnotics [86].”
BackgroundSelf-citationStahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
Stahl, S. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009053365 · Cited by 210
Self-citationTherapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Volpi, S., Potkin, S. G., Malhotra, A. K., Licamele, L., & Lavedan, C. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04391 · Cited by 204 · cited 1×
“Seventy-five per cent of iloperidone-treated patients with at least one genetic SNP showed at least 20% improvement in total Positive and Negative Syndrome Scale (PANSS) scores compared with only 37% of SNPfree iloperidone-treated patients who showed similar improvement [25].”
ResultIdentifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-V
Phillips, M. L., & Vieta, E. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm060 · Cited by 196
Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., & Loebel, A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04905 · Cited by 191 · cited 2×
“At the end point of different clinical trials, lurasidone did not cause significant clinical changes in total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein or fasting blood glucose [74].”
BackgroundNew Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine
Brunello, N. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00068-o · Cited by 191 · cited 1×
“Other adverse events such as lowering seizure threshold, cardiovascular toxicity, excessive sedation, significant weight gain, and a high incidence of hypertension and type II diabetes have also contributed to the limited use of clozapine [9-12].”
BackgroundMcIntyre, R. S., Cohen, M., Zhao, J., Alphs, L., Macek, T. A., & Panagides, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00748.x · Cited by 189 · cited 6×
“After 3 weeks of adjunctive treatment, asenapine improved symptoms of mania and significantly reduced YMRS total score more than placebo, which lasted for 12 weeks.”
BackgroundMethodInfluentialPotkin, S. G., & Cohen, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1004 · Cited by 175 · cited 2×
“At the end of treatment, asenapine improved PANSS-total, PANSS-positive and PANSSnegative scores versus placebo as early as 2 weeks of treatment [60].”
BackgroundPharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy
Mnie‐Filali, O., Faure, C., Lambás‐Señas, L., Mansari, M. E., Belblidia, H., Gondard, E., Etiévant, A., Scarna, H., Didier, A., Bérod, A., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.13 · Cited by 169 · cited 1×
“Asenapine’s and iloperidone’s high affinity and antagonistic activity at 5-HT7 receptors may support their potential efficacy in the treatment of uni-polar and bi-polar depression as blocking these receptors have been implicated in the pharmacotherapy of depression [78,79].”
BackgroundCardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Leung, J. Y. T., Barr, A. M., Procyshyn, R. M., Honer, W. G., & Pang, C. C. Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.003 · Cited by 163 · cited 1×
“Other adverse events such as lowering seizure threshold, cardiovascular toxicity, excessive sedation, significant weight gain, and a high incidence of hypertension and type II diabetes have also contributed to the limited use of clozapine [9-12].”
BackgroundLurasidone: a new drug in development for schizophrenia
Meyer, J. M., Loebel, A. D., & Schweizer, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286388 · Cited by 141 · cited 1×
“Lurasidone is metabolized through the CYP 3A4 pathway to produce onemajor metabolite ID-14283 (25% of parent exposure) and two minor metabolites ID14326 and ID11614 (3 and 1% of the parent exposure, respectively) [50].”
BackgroundCognitive impairment in schizophrenia
O'Carroll, R. (2000) · Advances in Psychiatric Treatment · doi:10.1192/apt.6.3.161 · Cited by 136 · cited 1×
“It has been suggested that cognitive impairments often precede development of psychotic symptoms of the disease, which further support the hypothesis that neurodevelopmental abnormalities contribute to the pathophysiology of schizophrenia [3].”
BackgroundCitrome, L. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02587.x · Cited by 130 · cited 2×
“7% for placebo), especially with the higher doses (80 -- 120 mg/day) of lurasidone [76].”
BackgroundCutler, A. J., Kalali, A. H., Weiden, P. J., Hamilton, J., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169d4ce · Cited by 113
Efficacy of Iloperidone in the Treatment of Schizophrenia: Initial Phase 3 Studies
Potkin, S. G., Litman, R. E., Torres, R., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181692787 · Cited by 102 · cited 4×
“A significant improvement in PANSStotal score was seen with the highest dose, and not with lower doses of iloperidone [56].”
BackgroundInfluentialKalkman, H. O., Subramanian, N., & Hoyer, D. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00285-8 · Cited by 99 · cited 1×
“Iloperidone has negligible affinity for muscarinic and histaminic receptors [23].”
BackgroundSafety Profile of Iloperidone: A Pooled Analysis of 6-Week Acute-Phase Pivotal Trials
Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181694f5a · Cited by 94 · cited 3×
“Mean changes in total cholesterol or fasting triglycerides from baseline were minimal after 52-week treatment with iloperidone [73].”
BackgroundMethodInfluentialIloperidone binding to human and rat dopamine and 5-HT receptors
Kongsamut, S., Roehr, J. E., Cai, J., Hartman, H. B., Weissensee, P., Kerman, L. L., Tang, L., & Sandrasagra, A. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00840-0 · Cited by 90 · cited 1×
“It has moderate affinity for 5-HT2C (Ki = 42 nM), 5-HT6 (Ki = 43 nM), 5-HT1A (Ki = 168 nM) and D1 (Ki = 216 nM) receptors [21].”
Szegedi, A., Calabrese, J. R., Stet, L., Mackle, M., Zhao, J., & Panagides, J. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f872f · Cited by 89 · cited 1×
“Adjunctive asenapine treatment also improved YMRS response and remission rates and reduced CGI-BP mania severity scores versus placebo recipients at week 12 [67].”
BackgroundAntipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management
Rege, S. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670801961123 · Cited by 88 · cited 1×
“However, these agents exhibit differences in terms of their efficacies, safety and adherence [14], and are also associated with undesirable side effects such as weight gain and metabolic deficits [15-18].”
BackgroundFrånberg, O., Wiker, C., Marcus, M. M., Konradsson‐Geuken, Å., Jardemark, K. E., Schilström, B., Shahid, M., Wong, E. H. F., & Svensson, T. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0973-y · Cited by 69 · cited 2×
“Acute asenapine administration increases dopamine, noradrenaline, serotonin and acetylcholine efflux in rat cortex [28,32,33].”
BackgroundCitrome, L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02142.x · Cited by 64
Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of Schizophrenia
Buchanan, R. W., Panagides, J., Zhao, J., Phiri, P., den Hollander, W., Ha, X., Kouassi, A., Alphs, L., Schooler, N., Szegedi, A., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f880a · Cited by 60 · cited 2×
“Both asenapine and olanzapine significantly and comparably reduced the 16-item Negative Symptom Assessment (NSA-16) total score from initial baseline after 26 weeks and 52 weeks of treatment [63].”
BackgroundGhanbari, R., Mansari, M. E., Shahid, M., & Blier, P. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.11.001 · Cited by 59
Huang, M., Li, Z., Dai, J., Shahid, M., Wong, E. H. F., & Meltzer, H. Y. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.20 · Cited by 54 · cited 1×
“Acute asenapine administration increases dopamine, noradrenaline, serotonin and acetylcholine efflux in rat cortex [28,32,33].”
BackgroundBarr, A. M., Powell, S. B., Markou, A., & Geyer, M. A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.004 · Cited by 53 · cited 1×
“Functional studies indicate that iloperidone acts as an antagonist at dopaminergic, serotonergic and noradrenergic receptors [24].”
BackgroundFrånberg, O., Marcus, M. M., Ivanov, V., Schilström, B., Shahid, M., & Svensson, T. H. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1456-5 · Cited by 52 · cited 1×
“Acute asenapine administration increases dopamine, noradrenaline, serotonin and acetylcholine efflux in rat cortex [28,32,33].”
BackgroundAsenapine effects in animal models of psychosis and cognitive function
Marston, H. M., Young, J. W., Martin, F., Serpa, K. A., Moore, C., Wong, E. H. F., Gold, L. H., Meltzer, L. T., Azar, M. R., Geyer, M. A., et al. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1570-z · Cited by 47
Agomelatine for the treatment of major depressive disorder
Carney, R. M., & Shelton, R. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.607812 · Cited by 45
Snigdha, S., Idris, N. F., Grayson, B., Shahid, M., & Neill, J. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2091-5 · Cited by 45 · cited 1×
“Asenapine is also active in several models of cognitive dysfunction as it attenuates phencyclidine [PCP]-induced deficits in reversal learning, and reverses PCP-induced disruption of novel object recognition memory in rats [30] and in monkeys [31].”
BackgroundDifferential regional and dose-related effects of asenapine on dopamine receptor subtypes
Tarazi, F. I., Moran‐Gates, T., Wong, E. H. F., Henry, B., & Shahid, M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1098-7 · Cited by 40 · cited 1×
“Chronic studies found that repeated administration of asenapine produces significant and dose-dependent changes in selective dopamine, serotonin, glutamate, and adrenergic and receptor subtypes in specific rat brain regions [34-36].”
BackgroundSelf-citationReceptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone
Subramanian, N., & Kalkman, H. O. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00307-4 · Cited by 39 · cited 2×
“Iloperidone is metabolized by CYP450 2D6 and 3A4 into two compounds with higher plasma levels than the parent compound: P88-8991 and P95-12113 [41].”
BackgroundAsenapine induces differential regional effects on serotonin receptor subtypes
Tarazi, F. I., Moran‐Gates, T., Wong, E., Henry, B., & Shahid, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108095704 · Cited by 39 · cited 1×
“Chronic studies found that repeated administration of asenapine produces significant and dose-dependent changes in selective dopamine, serotonin, glutamate, and adrenergic and receptor subtypes in specific rat brain regions [34-36].”
BackgroundSelf-citationElsworth, J. D., Groman, S. M., Jentsch, J. D., Valles, R., Shahid, M., Wong, E. H. F., Marston, H. M., & Roth, R. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.026 · Cited by 37 · cited 1×
“Asenapine is also active in several models of cognitive dysfunction as it attenuates phencyclidine [PCP]-induced deficits in reversal learning, and reverses PCP-induced disruption of novel object recognition memory in rats [30] and in monkeys [31].”
BackgroundCase Studies: Stahl's Essential Psychopharmacology
Stahl, S. M., & Muntner, N. (2011) · Cambridge University Press eBooks · doi:10.1017/9780521182089 · Cited by 36
Self-citationAsenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain
Tarazi, F. I., Choi, Y. K., Gardner, M., Wong, E. H. F., Henry, B., & Shahid, M. (2009) · Synapse · doi:10.1002/syn.20618 · Cited by 34 · cited 1×
“Chronic studies found that repeated administration of asenapine produces significant and dose-dependent changes in selective dopamine, serotonin, glutamate, and adrenergic and receptor subtypes in specific rat brain regions [34-36].”
BackgroundSelf-citationIloperidone: Preclinical Profile and Early Clinical Evaluation
Corbett, R., Griffiths, L., Shipley, J. E., Shukla, U. K., Strupczewski, J. T., Szczepanik, A. M., Szewczak, M. R., Turk, D. J., Vargas, H. M., Kongsamut, S., et al. (1997) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1997.tb00320.x · Cited by 29 · cited 1×
“At the end of treatment, significant dose-dependent improvements from baseline in PANSS total score were seen in iloperidone-treated patients compared to placebo [55].”
ResultAlbers, L. J., Musenga, A., & Raggi, M. A. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.61 · Cited by 24 · cited 1×
“1 Iloperidone Iloperidone has good oral absorption with a bioavailability of 96% [39].”
BackgroundNeurological and Psychiatric Disorders: From Bench to Bedside
Parish, R. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g149 · Cited by 7
McIntyre, R. S., Panagides, J., Alphs, L. D., Cohen, M., Lancaster, S., & Macek, T. A. (2007) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(07)70567-9 · Cited by 6
Metadata
- Authors
- Tarazi, F. I., & Stahl, S. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2012-07-31
- Volume
- 13
- Issue
- 13
- Pages
- 1911-1922
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2085168171
- Cited by
- 196
- References
- 63
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.